[Congressional Record Volume 171, Number 34 (Thursday, February 20, 2025)]
[Senate]
[Page S1184]
From the Congressional Record Online through the Government Publishing Office [www.gpo.gov]

  SA 374. Ms. CORTEZ MASTO (for herself, Ms. Alsobrooks, and Mr. Kim) 
submitted an amendment intended to be proposed by her to the concurrent 
resolution S. Con. Res. 7, setting forth the congressional budget for 
the United States Government for fiscal year 2025 and setting forth the 
appropriate budgetary levels for fiscal years 2026 through 2034; which 
was ordered to lie on the table; as follows:

       At the end of title III, add the following:

     SEC. 3___. DEFICIT-NEUTRAL RESERVE FUND RELATING TO LOWERING 
                   PRESCRIPTION DRUG PRICES.

       The Chairman of the Committee on the Budget of the Senate 
     may revise the allocations of a committee or committees, 
     aggregates, and other appropriate levels in this resolution, 
     and make adjustments to the pay-as-you-go ledger, for one or 
     more bills, joint resolutions, amendments, amendments between 
     the Houses, motions, or conference reports relating to 
     lowering prescription drug prices, which may include imposing 
     monetary penalties on drug manufacturers with respect to 
     prescription drug sales in the commercial market if the 
     average price of such drugs increases faster than the rate of 
     inflation or implementing other policies that penalize drug 
     manufacturers for increasing drug prices faster than 
     inflation, by the amounts provided in such legislation for 
     those purposes, provided that such legislation would not 
     increase the deficit over the period of the total of fiscal 
     years 2025 through 2034.
                                 ______